Pendopharm announces the launch of Octasa® 1600 mg tablets in Canada

Pendopharm, a division of Pharmascience Inc., is pleased to announce the recent launch of Octasa® 1600 mg, the highest-strength delayed-release mesalamine tablets, indicated for the induction of remission of moderate active ulcerative colitis (UC) in Canada.

Pendopharm is expanding the Octasa® family in Canada with the launch of Octasa® 1600 mg which represents an important step in Pendopharm’ strategic partnership with Tillotts Pharma AG, part of the Japanese Zeria Group, and a milestone for both organizations.

The introduction of Octasa® 1600 mg (mesalamine) delayed-release tablets to the Canadian market is expected to increase the options for patients suffering from ulcerative colitis managed with mesalamine.

Jad Isber, Vice President and General Manager at Pendopharm, said:

“Earlier this year, we announced the launch of Octasa® 800 mg, and we are delighted to continue our strong relationship with Tillotts by bringing Octasa® 1600 mg to Canadian patients suffering from moderately active ulcerative colitis. The addition of Octasa® 1600 mg to our portfolio will further enhance Pendopharm’s leadership position in gastroenterology, bringing a new treatment option to healthcare professionals and patients.”

Adrian Hill, Global Head of Commercial Operations at Tillotts, added:

“Tillotts has a longstanding history of more than 40 years in delivering mesalamine formulations for the treatment of patients suffering from UC.  I am very excited about the opportunity to strengthen our commercial presence in Canada by launching Octasa® 1600 mg tablet as a new high strength mesalamine tablet treatment option.

This has been achieved through the solid strategic partnership between Tillotts and Pendopharm.”


About Pharmascience Inc.

Pharmascience Inc. is one of the largest pharmaceutical manufacturers in Canada and is headquartered in Montreal, Canada. Pharmascience delivers high-quality medicines to over 50 countries worldwide. Pharmascience’s global presence and agile business development model provide healthcare communities around the world with the high-quality Canadian medicines to respond to patients’ needs.


About Pendopharm

Pendopharm, a division of Pharmascience Inc., is a leading Canadian specialty pharmaceutical company providing patients with innovative medicines that address unmet medical needs. Its areas of focus are gastroenterology, sports medicine & orthopedics, neurology and cardiology. Pendopharm has extensive experience and knowledge to successfully manage its growing product portfolio.

For more information about Pendopharm, please visit

For media inquiries, please contact [email protected].

© 2023 Pendopharm, a division of Pharmascience Inc. All rights reserved


About Tillotts

Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 350 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialization of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD and Clostridoides difficile infection (CDI) as well as in-licensed products in around 65 countries through its affiliates within Europe and a network of partners throughout the world.

The rights to the trademark Octasa® are owned by Tillotts Pharma AG used under license by Pendopharm, a division of Pharmascience Inc.

For more information, please visit


About Zeria

Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries. For more information about Zeria, please visit


For more information, please contact:

Tillotts Pharma
Jeroen van Anraat
Manager Corporate Communication
Phone: +41 79 692 6391
Email: [email protected]

Published in

Product Launches